Knowledge Hub

Tumor Necrosis Factor Receptor Superfamily Member 9 -Pipeline Review, H2 2017

Press Release   •   Nov 03, 2017 05:50 EDT

"
According to the recently published report Tumor Necrosis Factor Receptor Superfamily Member 9-Pipeline Review, H2 2017; Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes.
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)-Tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD137 is a member of the tumor necrosis factor (TNF) receptor family. CD137 is expressed by activated T cells (but to a larger extent on CD8 than on CD4 T cells). CD137 are involved in the regulation of a wide range of immune activities.
Get Sample Copy Of This Report @ https://www.marketresearchreports.biz/sample/sample/1361354
The report Tumor Necrosis Factor Receptor Superfamily Member 9-Pipeline Review, H2 2017 outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 9 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastric Cancer, Metastatic Breast Cancer, Metastatic Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Thyroid Cancer, B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Cervical Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Lymphoma, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Muscle Invasive Bladder Cancer (MIBC), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Cancer, Primary Mediastinal B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Sarcomas, Small-Cell Lung Cancer and Thymoma (Thymic Epithelial Tumor).
View Report @https://www.marketresearchreports.biz/reports/1361354/tumor-necrosis-factor-receptor-superfamily-member-9-4-1bb-ligand-receptor-or-t-cell-antigen-4-1bb-homolog-or-t-cell-antigen-ila-or-cd137-or-tnfrsf9-pipeline-review-h2-2017-market-research-reports
Scope
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)

- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics and enlists all their major and minor projects

- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1361354
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)-Overview

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)-Companies Involved in Therapeutics Development

Agenus Inc

Alligator Bioscience AB

Apogenix GmbH

BioInvent International AB

Eli Lilly and Co